# Adjuvant Immune Checkpoint Inhibitor Versus Observation After Neoadjuvant Immunochemotherapy and Surgery in High-Risk NSCLC

> **NCT07748325** · PHASE2 · RECRUITING · sponsor: **Sichuan University** · enrollment: 100 (estimated)

## Conditions studied

- Non-Small Cell Lung Cancer
- Adjuvant Therapy
- Immune Checkpoint Inhibitors

## Interventions

- **DRUG:** Sintilimab

## Key facts

- **NCT ID:** NCT07748325
- **Lead sponsor:** Sichuan University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-01-10
- **Primary completion:** 2027-12-30
- **Final completion:** 2028-12-30
- **Target enrollment:** 100 (ESTIMATED)
- **Last updated:** 2026-08-05


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07748325

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07748325, "Adjuvant Immune Checkpoint Inhibitor Versus Observation After Neoadjuvant Immunochemotherapy and Surgery in High-Risk NSCLC". Retrieved via MORVS 2026-10-20 from https://api.morvs.ai/clinical/NCT07748325. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*